Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 541-551 , July 2007

Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial α7 nicotinic cholinergic agonist drug

  • Sung Won Kim

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA
    • Corresponding Author InformationCorresponding author. Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA. Tel.: +1 631 344 4393; fax: +1 631 344 5815.
    • ,
  • Yu-Shin Ding

      Affiliations

    • Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA
    • Department of Radiology, Yale University School of Medicine, New Haven, CT 06520-8048, USA
    • ,
  • David Alexoff

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Vinal Patel

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Jean Logan

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Kuo-Shyan Lin

      Affiliations

    • Department of Radiology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    • ,
  • Colleen Shea

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Lisa Muench

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Youwen Xu

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Pauline Carter

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Payton King

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Jasmine R. Constanzo

      Affiliations

    • Department of Chemistry, Fordham University, Bronx, NY 10458, USA
    • ,
  • James A. Ciaccio

      Affiliations

    • Department of Chemistry, Fordham University, Bronx, NY 10458, USA
    • ,
  • Joanna S. Fowler

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA
    • Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA

Received 12 February 2007 ,Revised 2 April 2007 ,Accepted 10 April 2007.

References 

  1. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci. 2006;27:482–491
  2. Fagerstrom K, Balfour DJ. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs. 2006;15:107–116
  3. Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat. 2000;20:281–298
  4. Ding YS, Fowler JS. New-generation radiotracers for nAChR and NET. Nucl Med Biol. 2005;32:707–718
  5. Mazurov A, Hauser T, Miller CH. Selective alpha 7 nicotinic acetylcholine receptor ligands. Curr Med Chem. 2006;13:1567–1584
  6. Berg DK, Conroy WG. Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol. 2002;53:512–523
  7. Cilia J, Cluderay JE, Robbins MJ, Reavill C, Southam E, et al. Reversal of isolation-rearing-induced PPI deficits by an alpha 7 nicotinic receptor agonist. Psychopharmacology (Berl). 2005;182:214–219
  8. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, et al. SSR180711, a novel selective [alpha]7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology. 2006;32:1–16
  9. de Fiebre NC, de Fiebre CM. alpha(7) Nicotinic acetylcholine receptor-mediated protection against ethanol-induced neurotoxicity. Alcohol. 2003;31:149–153
  10. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem. 2000;275:5626–5632
  11. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol. 2007;17:145–155
  12. Kem W, Soti F, Wildeboer K, LeFrancois S, MacDougall K, et al. The nemertine toxin anabaseine and its derivative DMXBA (GTS21): chemical and pharmacological properties. Marine Drugs. 2006;4:255–273
  13. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology. 2003;28:542–551
  14. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, et al. Proof-of-concept trial of an alpha 7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63:630–638
  15. de Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. Mol Pharmacol. 1995;47:164–171
  16. Machu TK, Hamilton ME, Frye TF, Shanklin CL, Harris MC, et al. Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine(3A) receptor. J Pharmacol Exp Ther. 2001;299:1112–1119
  17. Zoltewicz JA, Prokaitatrai K, Bloom LB, Kem WR. Long-range-transmission of polar effects in cholinergic 3-arylideneanabaseines — conformations calculated by molecular modeling. Heterocycles. 1993;35:171–180
  18. Kem WR. A study of occurrence of anabaseine in Paranemertes and other nemertines. Toxicon. 1971;9:23–32
  19. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 1995;674:252–259
  20. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav. 1997;57:231–241
  21. Meyer EM, Tay ET, Zoltewicz JA, Meyers C, King MA, et al. Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther. 1998;284:1026–1032
  22. Meyer EM, Defiebre CM, Hunter BE, Simpkins CE, Frauworth N, Defiebre NEC. Effects of anabaseine-related analogs on rat-brain nicotinic receptor-binding and on avoidance behaviors. Drug Development Research. 1994;31:127–134
  23. Woodruffpak DS, Li YT, Kem WR. A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor-binding in rabbit brain. Brain Res. 1994;645:309–317
  24. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, et al. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem. 1999;73:1635–1640
  25. Kem WR. The brain [alpha]7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000;113:169–181
  26. Stevens KE, Kem WR, Mahnir VM, Freedman R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl). 1998;136:320–327
  27. Tatsumi R, Fujio M, Satoh H, Katayama J, Takanashi S, et al. Discovery of the alpha 7 nicotinic acetylcholine receptor agonists. (R)-3′-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5′-[1′,3′]-oxazolidin-2′-one as a novel, potent, selective, and orally bioavailable ligand. J Med Chem. 2005;48:2678–2686
  28. Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL. Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors. J Pharmacol Exp Ther. 1998;287:918–925
  29. Kem WR, Mahnir VM, Prokai L, Papke RL, Cao XF, et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol. 2004;65:56–67
  30. Kem RW, Zoltewicz AJ, Meyer ME, Prokai-tatrai K. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system. US Patent 5,741,802; 1998.
  31. Ding YS, Lin KS, Logan J, Benveniste H, Carter P. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([C-11]methylreboxetine, 3-Cl-[C-11]methylreboxetine and [F-18]fluororeboxetine), (R)-[C-11]nisoxetine, [C-11]oxaprotiline and [C-11]lortalamine. J Neurochem. 2005;94:337–351
  32. Delrosario RB, Jung YW, Baidoo KE, Lever SZ, Wieland DM. Synthesis and in-vivo evaluation of a Tc-99m/99-Dadt-Benzovesamicol — a potential marker for cholinergic neurons. Nucl Med Biol. 1994;21:197–203
  33. Black KJ, Snyder AZ, Koller JM, Gado MH, Perlmutter JS. Template images for nonhuman primate neuroimaging: 1. Baboon. Neuroimage. 2001;14:736–743
  34. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, et al. Graphical analysis of reversible radioligand binding from time–activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–747
  35. Alexoff DL, Shea C, Fowler JS, King P, Gatley SJ, et al. Plasma input function determination for PET using a commercial laboratory robot. Nucl Med Biol. 1995;22:893–904
  36. Alexoff DL, Vaska P, Marsteller D, Gerasimov T, Li J, et al. Reproducibility of C-11-raclopride binding in the rat brain measured with the MicroPET R4: effects of scatter correction and tracer specific activity. J Nucl Med. 2003;44:815–822
  37. Dischino DD, Welch MJ, Kilbourn MR, Raichle ME. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med. 1983;24:1030–1038
  38. Kulak JM, Musachio JL, McIntosh JM, Quik M. Declines in different beta 2*nicotinic receptor populations in monkey striatum after nigrostriatal damage. J Pharmacol Exp Ther. 2002;303:633–639
  39. Kulak JM, Schneider JS. Differences in [alpha]7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. Brain Res. 2004;999:193–202
  40. Azuma R, Hirota T, Manabe H, Komuro M, Kiwada H. First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference. Eur J Pharm Sci. 2001;14:159–165

PII: S0969-8051(07)00101-1

doi: 10.1016/j.nucmedbio.2007.04.005

Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 541-551 , July 2007

Article Tools

* Image Usage & Resolution